Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 593-598

  Kuroda, Yasufumi ^a   Hirayama, Chie ^b   Hotoda, Hitoshi ^b   Nishikawa, Yasuhiro ^b   Nishiwaki, Akinori ^b  

^a DAIICHI SANKYO INC   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Early postmarketing phase vigilance; Edoxaban; Factor Xa; Spontaneous reporting; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EDOXABAN; HEMOGLOBIN;

ABNORMAL FECES; AGED; ANEMIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDEMA; FEMALE; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEMARTHROSIS; HEMATEMESIS; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HIP SURGERY; HUMAN; HYPERBILIRUBINEMIA; JAPAN; JAUNDICE; JOINT SWELLING; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; ORTHOPEDIC SURGERY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RASH; RECTUM HEMORRHAGE; STOMACH HEMORRHAGE; SUBCUTANEOUS HEMORRHAGE; THROMBOCYTE COUNT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM; WOUND HEMORRHAGE;

EARLY POSTMARKETING PHASE VIGILANCE; EDOXABAN; FACTOR XA; SPONTANEOUS REPORTING; THROMBOPROPHYLAXIS; VENOUS THROMBOEMBOLISM;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; JAPAN; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PYRIDINES; RISK FACTORS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84889805341     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S51244     Document Type: Article

References (23)

1. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-727.
2. Sudo A, Sano T, Horikawa K, Yamakawa T, Shi D, Uchida A. The incidence of deep vein thrombosis after hip and knee arthroplasties in Japanese patients: a prospective study. J Orthop Surg (Hong Kong). 2003;11(2):174-177.
3. National Institute for Health and Clinical Excellence. Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing. Manchester, UK: National Institute for Health and Clinical Excellence; 2012.
4. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e120S-e151S.
5. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370(9601):1773-1779.
6. Galioto NJ, Danley DL, Van Maanen RJ. Recurrent venous thromboembolism. Am Fam Physician. 2011;83(3):293-300.
7. Falck-Ytter Y, Francis CW, Johanson NA, et al; American College of Chest Physicians. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e278S-e325S.
8. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.8th ed. Chest. 2008;133(Suppl 6):381S-453S.
9. Lixiana [package insert]. Tokyo, Japan: Daiichi Sankyo Company, Ltd; 2011.
10. Raskob G, Büller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287-1294.
11. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-641.
12. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-1549.
13. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8(11):2458-2468.
14. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010;104(3):642-649.
15. Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial [Abstract]. Blood. 2010;116:3320.
16. Fuji T, Wang CJ, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial [Abstract]. Pathophysiol Haemost Thromb. 2010;37:OC297.
17. Fujita S, Fuji T, Tachibana S, Nakamura M, Kawai Y. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery [Abstract]. Pathophysiol Haemost Thromb. 2010;37:P366.
18. Ministry of Health, Labor and Welfare. [Guidelines for Implementation of Early Post-Marketing Phase Vigilance (EPPV) for Prescription Drugs]. 2006. Japanese. Available from http://www.info.pmda.go.jp/shinyaku/file/s20060324-001.pdf. Accessed on September 11, 2013.
19. International Federation of Pharmaceutical Manufacturers and Associations. Medical Dictionary for Regulatory Activities. MedDRA/J Version 14.1. 2011. Available from: http://www.meddra.org/sites/default/files/guidance/file/intguide_14_1_english.pdf. Accessed September 11, 2013.
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Post-Approval Safety Data Management: Definitions and Standards for Expediting Reporting E2D. Geneva, Switzerland: International Conference on Harmonisation; 2003. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf. Accessed April 3, 2013.
21. Nagase Y, Yasunaga H, Horiguchi H, et al. Risk factors for pulmonary embolism and the effects of fondaparinux after total hip and knee arthroplasty: a retrospective observational study with use of a national database in Japan. J Bone Joint Surg Am. 2011;93(24):e146.
22. Fuji T, Fujita S, Tachibana S, Kawai Y. Edoxaban versus enoxaparin for the prevention of venous thromboembolism: pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V. Blood. 2011;118(21):208. Available from: https://ash.confex.com/ash/2011/webprogram/Paper39023.html. Accessed September 11, 2013.
23. Kuroda Y, Hotoda H, Nishikawa Y, Nishiwaki A. Post-Marketing Safety Experience with Edoxaban in Japan for Thromboprophylaxis Following Major Orthopedic Surgery. Blood. 2012;120: 4697(Abstract). Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4697?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=post-marketing&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT. Accessed September 27, 2013.